AHA: DAPD-CKD investigator Prof John McMurray talks to Patient Care about the “revolutionary” findings he will highlight at the AHA sessions on opening day.
Finerenone, a non-steroidal, selective MRA, has distinct advantages over current treatments for diabetic kidney disease. Dr Bakris details these and the FIDELIO results.
Waist circumference measures, complementary antihypertensives, appropriate exercise levels for T2D patients--test what you know about cardiometabolic risk and management.
Dapagliflozin is renoprotective and cardioprotective in chronic kidney disease patients, suggests a secondary analysis of the DAPA-CKD trial presented at Kidney Week 2020.
The investigational mineralocorticoid receptor antagonist slowed progression to renal failure by 18% and reduced the composite cardiovascular outcome by 14%, authors report.
FDA Fast Track designation is to investigate whether the diabetes medication can also reduce kidney disease progression.
Cardiovascular diseases, particularly heart failure, were found significantly and independently associated with end-stage renal disease in a new analysis.
When CKD 4-5 progresses to ESRD, how should hypertension management be changed? Or, should it?
New risk prediction models may help identify patients with and without diabetes at elevated risk for chronic kidney disease, say authors of a recent study.
Transitioning from urgent, unplanned inpatient dialysis to home hemodialysis was linked to higher risk of mortality in a new registry analysis.